CO220 Real-World Effectiveness and Safety in a Phase 4 Study of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis

Abstract

Tildrakizumab is an anti–interleukin-23 p19 monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis. This analysis assesses effectiveness and safety of tildrakizumab from a real-world study of patients with moderate-to-severe plaque psoriasis.